| Ytd | 79.94% | |
| 1y | 184.73% |
| Open | 75.00 | Prev Close | 73.64 | Low | 73.43 | High | 76.22 | Mkt Cap | 2.18B |
| Vol | 0.00 | Avg Vol | 947.08K | EPS | -8.40 | P/E | -9.06 | Forward P/E | -7.02 |
| Beta | 1.16 | Short Ratio | 6.99 | Inst. Own | 106.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 68.27 | 200-d Avg | 63.88 | 1yr Est | 153.22 |
NKTR News
Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atop
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-s
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpeg
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consen
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage bi
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) will likely be releasing its Q2 2026 results af
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its fi
The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in N
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares gapped up before the market opened on Fr
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, wi
Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) wit
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon cl
Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon c
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that
Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted averag
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that,
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidat
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
On Friday, 469 companies hit new 52-week lows.
On Wednesday, 116 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Monday, 466 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday